Low-Dose 5-Aza-2'-Deoxycytidine, a DNA Hypomethylating Agent,
for the Treatment of High-Risk Myelodysplastic Syndrome: A
Multicenter >Phase II Study in Elderly Patients > > http://www.jco.org/cgi/content/abstract/18/5/956 > >PURPOSE:
5-Aza-2'-deoxycytidine (decitabine; DAC) is a DNA hypomethylating agent that has
shown a 50% response rate in a small phase >II study in elderly patients
with high-risk myelodysplastic syndrome. We performed a second, multicenter
phase II study in a larger >group of patients to confirm our findings and
to study the toxicity of DAC > > >
